HeartFlow, Inc. (HTFL) Q4 2025 Earnings Call Transcript

HeartFlow held its Q4 2025 earnings call on March 18, 2026 with CEO John Farquhar and CFO Vikram Verghese discussing Q4 and full-year 2025 performance. Management outlined commercial momentum, the innovation pipeline and clinical programs and said financial guidance is being provided; the earnings release and non-GAAP reconciliations are available on the company IR site. The call included participation from sell-side analysts and reiterated forward-looking statement cautions.

Analysis

HeartFlow’s revenue cadence and guidance will be driven less by a single quarter and more by the timing of three multi-year levers: payer coverage wins, health system contract rollouts, and upgrades to CT throughput that enable scale. Each lever has asymmetric lead times — payer decisions and guideline endorsements operate on 6–24 month cycles, while hospital technology adoption follows annual budget windows; this means near-term beats can be transient unless embedded into system pathways.

The most underappreciated second-order effect is on procedure mix: sustained displacement of invasive diagnostic angiography by noninvasive CFD-enabled CCTA shifts margin pools away from cath-lab consumables and toward imaging software/subscription economics. That transition creates winners in recurring-revenue software providers and radiology service platforms while exerting steady, multi-quarter pressure on interventional device volumes and procedure-driven hospital revenue centers.

Key tail risks are adoption stall from payer pushback and commoditization of FFR-CT by low-cost AI competitors; either can compress ASPs and elongate customer payback beyond the 12–24 month window investors model. Conversely, a clear, multi-payer reimbursement pathway or a major IDN roll that embeds the solution in care pathways would be a binary catalyst that can accelerate ARR growth and expand gross margins materially over 12–36 months.

Key Decisions for Investors

• Buy HTFL equity (12-month horizon): Initiate a position with a 30–40% capital allocation of a target internal portfolio tilt to medical AI, set a 12-month upside target of +50–70% conditional on continued commercial cadence and payer wins; hard stop at -25–30% below entry to protect against reimbursement disappointments.
• Long-dated, structured option (18–24 months): Buy LEAP calls on HTFL (Jan 2027) and finance with short-dated calls (3–6 months) to create a call spread; this caps downside premium decay while giving asymmetric upside if a major payer/IDN endorsement occurs. Risk: full premium loss if clinical/reimbursement catalysts miss; Reward: ~3:1 if adoption accelerates into 2026–2027.
• Pair trade to express structural mix shift (12–24 months): Long HTFL vs short a high-beta interventional device name (e.g., BSX or ABT) to capture margin rotation from cath labs to noninvasive diagnostics. Position size no greater than 1.5:1 long/short notional; thesis wins if noninvasive share of diagnostic CAD exams grows by 5–10% over 12–24 months, but cut if overall CAD procedural volumes recover or guideline updates favor invasive strategies.
• Risk hedge / catalyst monitor: Maintain a macro hedge (e.g., modest put protection on broad healthcare ETFs) sized to cover 20–30% of HTFL exposure through next two quarters given event risk (payer decisions, guidance updates). Trigger to add conviction: publication of multi-center registry or a major payer coverage memo — reduce hedge and take profits within 4–8 weeks after confirmation.